RE: ORPH Research note - Imutex deal 'near to fruition'2 Oct 2020 11:48
Ok you have drawn me out of my slumber to voice my opinion. The valuation of orph group outlined in the broker projections of current pipe line deals using balance sheet assets is circa 18-22p. That is the group balance sheet assets which, of course do not provide valuations on immutex which is just a shell company with no declared assets just directors (but clearly has IP in a vaccine candidate).
Likewise the valuation of other non balance sheet assests (data) is not a tangible asset per se'.
So all things remaining equal, the company at this time is on par with valuations, therefore any actionable sales of Immutex or the other data should cause the SP to re-rate to the implied balance sheet value of those assets at that point in time. One can thereafter reasonably expect a fall back from the new SP when the transfer of capital take place between the company and the shareholders. In simple terms it is not priced per se' because it can't be.. The benefit of the existence of the potential assets is to make shares sticky on potential even when it cant be costed... That for what it is worth is my opinion on the situation here and FOMO is a key driver going forward alongside contract news.. Cheers all - back to sleep